Skip to main content
An official website of the United States government
Dr. Jeffrey Hildesheim

Jeffrey Hildesheim, Ph.D.

Division of Cancer Biology (DCB)

Dr. Jeffrey Hildesheim is Chief of the Tumor Biology and Microenvironment Branch, and he co-leads several trans-NCI programs that bridge basic and translational cancer research. He is interested in research investigating the dynamics of the tumor and the tumor microenvironment as co-organizers in tumor initiation, progression and response to therapy.

In addition to his work for DCB, Dr. Hildesheim also co-chairs a Cancer Moonshot Implementation Team and is involved with the NCI - Dept. of Energy IMPROVE collaborative project, NCI SBIR Advisory Group, as well as the CTEP Molecular Profiling Clinical Trials/Tumor Board Panel and Drug Development Program. He also serves as the DCB representative on the NCI internal Clinical and Translational Research Operations Committee. 


Research Programs:  

Dr. Hildesheim co-leads NCI cooperative agreement programs and a Cancer Moonshot initiative: 



Prior to becoming a branch chief, Dr. Hildesheim was a program director in DCB’s Cancer Cell Biology Branch where he managed a grant portfolio in cell cycle regulation, post-translational modification, and senescence, among other forms of cell state and plasticity. 

Dr. Hildesheim’s research background includes development of human disease-relevant mouse models and 3D tissue culture platforms to elucidate the mechanistic underpinnings of epidermal-dermal dynamics, keratinocyte differentiation and stratification processes in homeostasis, and a variety of skin disorders (including cancer). He also studied stress MAPK signaling and Gadd45a in regulating UV-induced skin inflammation and tumorigenesis. 



  • Ph.D., Genetics, George Washington University
  • M.S, Genetics, George Washington University
  • B.A., Biology, Washington University in St. Louis